The deadline to submit an abstract for short talk and poster presentation consideration has passed. For any questions or issues, please email info@keystonesymposia.org.

Fatty liver disease (FLD) comprises a spectrum of conditions in which excess in liver fat coexists with inflammation, fibrosis and increased risk of cancer. The incidence and prevalence of FLD is increasing rapidly, affecting  approximately one in four people globally, with concurrent increases in liver related morbidity and mortality.  Despite more than a decade of research from academia and industry, clinical trials have failed to bring effective treatments for FLD with fibrosis. The complex and variable interactions between environmental and genetic susceptibility and protective factors have played central roles.  Assessing severity of disease and response to therapy have been similarly challenging. 

This meeting will dive into FLD metabolic, genetic and molecular diversity to identify novel strategies to tackle this disease. The program will examine the latest advances in noninvasive measurements to both assess treatment efficacy and identify subpopulations at risk for liver related events and mortality. Sessions will explore novel drug targets deriving from human genetics studies of variants protective against FLD. Ultimately, these advances will pave the way to precision therapeutics to treat MASH, fibrosis and cancer.